

Renaud A. Du Pasquier



[Renaud A. Du Pasquier](#), M.D.
Full Professor

2015-present:

Full Professor at the Faculty of Biology and Medicine of the University of Lausanne Chairman of the Service of neurology
Head of the Laboratory of neuroimmunology
Department of clinical neurosciences, CHUV, Lausanne.

2011-2014:

Associate professor, médecin adjoint
Service of neurology, Department of clinical neurosciences; and Service of immunology and allergy, Department of medicine, CHUV, Lausanne

2005-2011:

Assistant Professor, Médecin associé
Divisions of Neurology and of Immunology and Allergy, CHUV, Lausanne.

September 2007-June 2008:

Acting Chairman in the Division of Neurology, CHUV, Lausanne.

2005:

Recipient of the Swiss National Foundation Professorship.

1999-2004:

Post-doc, then Instructor (Neurology and Division of Viral Pathogenesis, Prof. I.J. Koralnik), BIDMC, Harvard Medical School, Boston Massachusetts, USA. Research project: "*Study of the role of CD8⁺ T cells in Progressive Multifocal Leukoencephalopathy, a demyelinating disease of the central nervous system caused by the polyomavirus JC*".

2004:

Board-certified in Internal Medicine.

2001:

Board-certified in Neurology.

1997:

Thesis in Medicine, University of Geneva.

1992:

Diploma of Medicine, University of Geneva.

Awards

- **2010:**
Faculty Price 2010 (Faculty of Biology and Medicine - FBM, University of Lausanne) for the E. Jaquiéry's work entitled: "Intrathecal immune response to EBV in early MS" published in European Journal of Immunology.
- **2009:**
Best Poster in Basic Clinical Research at the Annual Congress of the Swiss Society for Allergology and Immunology 2009, Geneva. Increased EBV Reactivation in the Cerebrospinal Fluid of Patients with Early Multiple Sclerosis
(E. Jaquiéry, first author, R. Du Pasquier, last author).
- **2008:**
First BIOGEN DOMPE award for Clinical Research into Multiple Sclerosis (S. Jilek, first author and R. Du Pasquier, last author).
- **2007:**
Recipient of the Abbott prize for the second best project submitted to the Swiss HIV Cohort Study in 2006
(R. Du Pasquier, principal investigator).

Selected publications

(<http://www.unil.ch/unisciences/renauddupasquier>)

- Bacchetta F, Mathias A, Schlupe M, **Du Pasquier R**, Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: an intriguing coincidence, Multiple Sclerosis Journal, in press
- Mathias A, Perriard G, Canales M, Sorenson C, Delorenzi M, Schlupe M, **Du Pasquier RA**, Increased ex vivo antigen presentation profile of B cells in multiple sclerosis, Multiple Sclerosis Journal, in press
- Mathias A, Perriard G, Canales M, Vuilleumier F, Perrotta G, Schlupe M, **Du Pasquier RA**, The VZV/IE63-specific T cell response prevents herpes zoster in fingolimod-treated patients, Neurol Neuroimmunol Neuroinflamm 2016 Feb 10;3(2):e209
- Perriard G, Mathias A, Enz L, Canales M, Schlupe M, Gentner M, Scharen-Wiemers N, **Du Pasquier RA**, Interleukin-22 is increased in multiple sclerosis patients and targets astrocytes. J Neuroinflammation 2015 Jun 16;12(1):119
- Jilek S, Mathias A, Canales M, Lysandropoulos A, Pantaleo G, Schlupe M, **Du Pasquier RA**, Natalizumab treatment alters the expression of T cell trafficking markers LFA-1 α -chain (CD11a) and CXCR3 in MS patients. Mult Scler J 2014;20(7):837-42.
- **Du Pasquier RA**, Jilek S, Kalubi M, Yerly S, Fux C, Gutmann C, Cusini A, Günthard H, Cavassini M, Vernazza P. Marked increase of astrocytic Marker S100B in the cerebrospinal fluid of HIV-infected patients on LPV/r-monotherapy. AIDS 2013;27:203-10
- Simioni S, Cavassini M, Annoni JM, Michel M, Iglesias K, Rimbault Abraham A, Calmy A, Müller H, Fayet A, Giacobini E, Hirschel B, **Du Pasquier RA**. Rivastigmine for HIV-associated neurocognitive disorders: a randomized, double-blind, placebo-controlled, crossover study, Neurology 2013;80(6):553-60
- Antoniol C., Jilek S., Schlupe M., Mercier N., Canales M., Le Goff G., Campiche C., Pantaleo G. and **Du Pasquier R.A.** Impairment of JCV-specific T cell response by corticotherapy: impact on PML-IRIS management ? Neurology 2012, 79:2258-2264. [PudMed](#)
- **Du Pasquier R.A.**, Jilek S., Kalubi M., Yerly S., Fux C.A., Gutmann C., Cusini A., Günthard H.F., Cavassini M., Vernazza P.L. and the Swiss HIV Cohort Study. Marked Increase of the Astrocytic Marker S100B in the Cerebrospinal Fluid of HIV-infected Patients on LPV/r-Monotherapy. AIDS 2012. In press. [PubMed](#)

- Jilek S., Schlupe M., Pantaleo G. and **Du Pasquier R.A.** MOBP-specific cellular immune responses are weaker than MOG-specific cellular immune responses in patients with multiple sclerosis and healthy subjects. *Neurol. Sci.* 2012. In press. [PubMed](#)
- Jilek S., Schlupe M., Harari A., Canales M., Lysandropoulos A., Zekeridou A., Pantaleo G. and **Du Pasquier R.A.** HLA-B7-restricted EBV-specific CD8⁺ T cells are dysregulated in multiple sclerosis. *J. Immunol.* 2012, 188:4671-4680. [PubMed](#)
- Schwab N., Höhn K.G., Schneider-Hohendorf T., Metz I., Stenner M.P., Jilek S., **Du Pasquier R.A.**, Gold R., Meuth S.G., Ransohoff R.M., Brück W. and Wiendl H. Immunological and clinical consequences of treating a patient with natalizumab. *Mult. Scler.* 2012, 18:335-344. [PubMed](#)
- Schwab N., Ulzheimer J.C., Fox R.J., Schneider-Hohendorf T., Kieseier B.C., Monoranu C.M., Staugaitis S.M., Welch W., Jilek S., **Du Pasquier R.A.**, Brück W., Toyka K.V., Ransohoff R.M. and Wiendl H. Fatal PML associated with efalizumab therapy: Insights into integrin L β 2 in JC virus control. *Neurology* 2012, 78:458-467. [PubMed](#)
- Guarda G., Braun M., Staehli F., Tardivel A., Förster I., Farlik M., Decker T., **Du Pasquier R.A.**, Romero P. and Tschopp J. Type I IFN inhibits IL-1 production and inflammasome activation. *Immunity* 2011, 34:213-223. [PubMed](#)
- Kuntzer T., Carota A., Novy J., Cavassini M. and **Du Pasquier R.A.** Rituximab is successful in an HIV-positive patient with IRIS-induced MuSK myasthenia gravis. *Neurology* 2011, 76:757-758. [PubMed](#)
- Lysandropoulos A., Jaquiéry E., Jilek S., Pantaleo G., Schlupe M. and **Du Pasquier R.A.** Vitamin D has a direct immunomodulatory effect on CD8⁺ T cells of patients with early multiple sclerosis and healthy control subjects. *J. Neuroimmunol.* 2011, 233 :240-244. [PubMed](#)
- Cvetkovic-Lopes V., Bayer L., Dorsaz S., Maret S., Pradervand S., Dauvilliers Y., Lecendreau M., Lammers G., Donjacour C., **Du Pasquier R.A.**, Pfister C., Petit B., Mühlethaler M., and Tafti M. Tribbles homolog 2 as an autoantigen in human narcolepsy. *J. Clin. Invest.* 2010, 120:713-719. [PubMed](#)
- **Du Pasquier R.A.** A promenade along the stream of demyelination. *Curr. Opin. Neurol.* 2010, 23:203-204. [PubMed](#)
- Jaquiéry E., Jilek S., Schlupe M., Le Goff G., Garcia M., Pantaleo G. and **Du Pasquier R.A.** Cytokine mRNA profile of Epstein-Barr virus-stimulated highly differentiated T cells in multiple sclerosis: A pilot study. *J. Neuroimmunol.* 2010, 225:167-170. [PubMed](#)
- Jaquiéry E., Jilek S., Schlupe M., Meylan P., Lysandropoulos A., Pantaleo G. and **Du Pasquier R.A.** Intrathecal immune responses to Epstein-Barr virus in early multiple sclerosis. *Eur. J. Immunol.* 2010, 40:878-887. [PubMed](#)
- Jilek S., Jaquiéry E., Hirsch H.H., Lysandropoulos A., Canales M., Guignard L., Schlupe M., Pantaleo G. and **Du Pasquier R.A.** Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. *Lancet Neurology* 2010, 9:264-272. [PubMed](#)
- Lysandropoulos A.P. and **Du Pasquier R.A.** Demyelination as a complication of new immunomodulatory treatments. *Curr. Opin. Neurol.* 2010, 23:226-233. [PubMed](#)
- Simioni S., Cavassini M., Annoni J.-M., Rimbault-Abraham A., Bourquin I., Schiffer V., Calmy A., Chave J.-P., Giacobini E., Hirschel B. and **Du Pasquier R.A.** Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. *AIDS* 2010, 24:1243-1250. [PubMed](#)
- Jilek S., Schlupe M., Meylan P., Vingerhoets F., Guignard L., Monney A., Kleeberg J., Le Goff G., Pantaleo G. and **Du Pasquier R.A.** Strong EBV-specific CD8⁺ T cell response in patients with early multiple sclerosis. *Brain* 2008, 131:1712-1721. [PubMed](#)
- Jilek S., Kuhle J., Meylan P., Reichhart M.D., Pantaleo G. and **Du Pasquier R.A.** Severe post-EBV encephalopathy associated with myelin oligodendrocyte glycoprotein-specific immune response. *J. Neuroimmunol.* 2007, 192:192-197. [PubMed](#)
- Jilek S., Schlupe M., Rosseti A.O., Guignard L., Le Goff G., Pantaleo G. and **Du Pasquier R.A.** CSF enrichment of highly differentiated CD8⁺ T cells in early multiple sclerosis. *Clin. Immunol.* 2007, 123:105-113. [PubMed](#)
- Vulliemoz S., Lurati-Ruiz F., Borruat F.X., Delavelle J., Korálnik I.J., Kuntzer T., Bogousslavsky J., Picard F., Landis T. and **Du Pasquier R.A.** Favourable outcome of progressive multifocal leukoencephalopathy in two patients with dermatomyositis. *J. Neurol. Neurosurg. Psychiatry* 2006, 77:1079-1082. [PubMed](#)

- **Du Pasquier R.A.**, Stein M.C., Lima M.A., Dang X., Jean-Jacques J., Zheng Y., Letvin N.L. and Koralnik I.J. JC virus induces a vigorous CD8⁺ cytotoxic T cell response in multiple sclerosis patients. *J. Neuroimmunol.* 2006, 176:181-186. [PubMed](#)
- **Du Pasquier R.A.**, Autissier P., Zheng Y., Jean-Jacques J. and Koralnik I.J. Presence of JC virus-specific CTL in the cerebrospinal fluid of PML patients: rationale for immune-based therapeutic strategies. *AIDS* 2005, 19:2069-2076. [PubMed](#)
- **Du Pasquier R.A.**, Schmitz J.E., Jean-Jacques J., Zheng Y., Gordon J., Khalili K., Letvin N.L. and Koralnik I.J. Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals. *J. Virol.* 2004, 78:10206-10210. [PubMed](#)
- **Du Pasquier R.A.**, Kuroda M.J., Schmitz J.E., Zheng Y., Jean-Jacques J. and Koralnik I.J. A prospective study demonstrates an association between JCV-specific CTL and the early control of Progressive Multifocal Leukoencephalopathy. *Brain* 2004, 127:1970-1978. [PubMed](#)
- **Du Pasquier R.A.**, Schmitz J.E., Jean-Jacques J., Zheng Y., Gordon J., Khalili K., Letvin N. and Koralnik I.J. Detection of JC Virus-specific cytotoxic T lymphocytes in healthy individuals. *J. Virol.* 2004, 78:10206-10210. [PubMed](#)
- **Du Pasquier R.A.**, Kuroda M.J., Schmitz J.E., Zheng Y., Martin K., Peyerl F.W., Lifton M., Gorgone D., Autissier P., Letvin N. and Koralnik I.J. Low Frequency of cytotoxic T lymphocytes against the novel HLA-A*0201-restricted JC virus epitope VP1_{p36} in patients with proven or possible Progressive Multifocal Leukoencephalopathy. *J. Virol.* 2003, 77:11918-11926. [PubMed](#)
- **Du Pasquier R.A.**, Corey S., Margolin D.H., William K., Pfister L.A., Mc Key J.J., De Girolami U., Joseph J.T. and Koralnik I.J. Productive Infection of Cerebellar Granule Cell Neurons by JC Virus in an HIV-infected Individual with Progressive Multifocal Leukoencephalopathy. *Neurology* 2003, 61:775-782. [PubMed](#)
- Jilek S., Walter E., Merkle H.P. and Corthésy B. Modulation of allergic responses in mice using poly(lactide co-glycolide) biodegradable microparticles. *J. Allergy Clin. Immunol.* 2004, 114:943-950. [PubMed](#)
- Jilek S., Barbey C., Spertini F. and Corthésy B. Antigen-independent suppression of the allergic immune response to bee venom phospholipase A(2) by DNA vaccination in CBA/J mice. *J. Immunol.* 2001, 166:3612-3621. [PubMed](#)